The FDA grants ODD status to medicines and potential new medicines intended for the treatment, diagnosis or prevention of rare diseases or disorders that affect fewer than 200,000 people in the US
The country is sixth among the most affected countries by active cases
Pfizer is evaluating the FDA’s comments and will work with the agency to determine an appropriate path forward
Go-ahead for pivotal clinical trial which is expected to commence by March
The drug is to be supplied in 105 low and middle-income countries and 10 Indian firms are on the list
It is the first CAR T Therapy approved for the treatment of multiple myeloma in Japan
Quviviq is a dual orexin receptor antagonist, which blocks the binding of the wake-promoting neuropeptides orexins and is thought to turn down overactive wakefulness, as opposed to treatments that generally sedate the brain
Bio-catalysis and Electro-catalysis emerge as most preferred green chemistry technologies
This agreement allows Natco to expand access to Covid-19 medicines in 105 countries in generic name
Industry Report highlights the opportunities and need for multiple sectoral collaboration through 12 actionable recommendations under 6 thematic areas
Subscribe To Our Newsletter & Stay Updated
